{
    "clinical_study": {
        "@rank": "131001", 
        "arm_group": [
            {
                "arm_group_label": "NXN-462", 
                "arm_group_type": "Experimental", 
                "description": "capsule, 200 mg, bi.d. 28-days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "capsule, b.i.d. 28-days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is\n      effective in reducing pain levels in patients with post-herpetic neuralgia."
        }, 
        "brief_title": "Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Post Herpetic Neuralgia", 
        "condition_browse": {
            "mesh_term": [
                "Neuralgia", 
                "Neuralgia, Postherpetic"
            ]
        }, 
        "detailed_description": {
            "textblock": "NXN-462 is designed to target the nitric oxide synthase system (NOS), specifically the\n      neuronal NOS (nNOS) isoform. By design,  NXN-462 is a potent inhibitor of nNOS with good\n      affinity, and has little or no affinity for a range of G protein-coupled receptors, ion\n      channels, and enzymes. NXN-462 is being developed as an  oral therapy for the treatment of\n      neuropathic pain syndromes, including PHN. This drug design strategy provides a new\n      therapeutic paradigm for the treatment of chronic neuropathic pain."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, or a non-pregnant, non-lactating female 18 years or older\n\n          -  Have voluntarily provided written informed consent\n\n          -  able to speak, read, write, and understand English\n\n          -  clinical diagnosis of PHN for a minimum of 6 months\n\n          -  pain intensity score of \u22653 on a 0-10 Numerical Rating Scale (NRS) at the Screening\n             Visit\n\n          -  generally in good health (other than PHN) at Screening\n\n        Exclusion Criteria:\n\n          -  Are pregnant and/or lactating\n\n          -  Diagnosis of any chronic pain syndrome that would interfere with the assessment of\n             PHN\n\n          -  evidence of multiple causes of neuropathic pain,e.g.lumbar radiculopathy in the\n             lumbosacral area\n\n          -  Have had neuroablation or neurosurgical intervention for PHN\n\n          -  Have been taking opioid analgesics for >5 days/week\n\n          -  Have received nerve block or intrathecal analgesia within 6 weeks of the study\n\n          -  History of significant gastrointestinal disease, liver disease, renal disease,\n             endocrine disease, or cardiovascular disease\n\n          -  clinically significant abnormal clinical laboratory test results or vital signs\n\n          -  Are immunocompromised or immunosuppressed for any reason\n\n          -  History of alcohol or other substance abuse (not including nicotine or tobacco)\n             within 5 years\n\n          -  Significant psychiatric disorder which requires drug treatment (except depression or\n             anxiety treated with Selective Serotonin Re-uptake Inhibitors)\n\n          -  Have received an investigational drug or have used an investigational device within\n             30 days of Screening.\n\n          -  Have previously been randomized to this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748877", 
            "org_study_id": "NXN-462-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "NXN-462", 
                "description": "Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.", 
                "intervention_name": "NXN-462", 
                "intervention_type": "Drug", 
                "other_name": "NXN-462 dihydrochloride"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken  preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "shingles,", 
            "neuropathic pain", 
            "post herpetic neuralgia", 
            "sleep"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85027"
                    }, 
                    "name": "Premier Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern California"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95821"
                    }, 
                    "name": "Northern California Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Neurological Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooksville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34601"
                    }, 
                    "name": "Meridien Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kissimmee", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34741"
                    }, 
                    "name": "FPA Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Port Richey", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Suncoast Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Compass Research LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "Meridien Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60602"
                    }, 
                    "name": "Medex Healthcare Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Des Moines", 
                        "country": "United States", 
                        "state": "Iowa"
                    }, 
                    "name": "Integrated Clinical Trial Services"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Towson", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21204"
                    }, 
                    "name": "IRC Clinics"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02131"
                    }, 
                    "name": "Boston Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Michigan Head-Pain and Neurological Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87102"
                    }, 
                    "name": "Albuquerque Clinical Trials, Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hickory", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "01845"
                    }, 
                    "name": "Clinical Trials of America, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73112"
                    }, 
                    "name": "Lynn Health Science Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mt. Pleasant", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Pain Specialist of Charleston, P.A."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Nashville Neuroscience Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tullahoma", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37388"
                    }, 
                    "name": "Trinity Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plano", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75080"
                    }, 
                    "name": "ClinRx Research LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Progressive Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V6J 1S3"
                    }, 
                    "name": "Manna Research Vancouver"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9W 4L6"
                    }, 
                    "name": "Manna Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pointe-Claire", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9R 4S3"
                    }, 
                    "name": "Kells Medical Research Group - Manna Research"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)", 
        "overall_official": {
            "affiliation": "NeurAxon Inc.", 
            "last_name": "Thomas Lategan, D.Phil.", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline to the last week of treatment in daily (24-hour recall) pain scores comparing NXN-462 with placebo", 
            "measure": "Change from baseline to the last week of treatment in daily pain scores", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748877"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "average weekly change in pain score from baseline to the end of the Treatment Period", 
                "safety_issue": "No", 
                "time_frame": "four weeks"
            }, 
            {
                "measure": "Analysis of percent change from baseline in daily pain score", 
                "safety_issue": "No", 
                "time_frame": "four weeks"
            }, 
            {
                "description": "subjects with a \u226530% and  \u226550% reduction in pain score from baseline to the last week of treatment", 
                "measure": "percentage of responders", 
                "safety_issue": "No", 
                "time_frame": "four weeks"
            }, 
            {
                "measure": "Percentage of subjects with moderate or much improvement at the end of the Treatment Period, according to Patient Global Impression of Change", 
                "safety_issue": "No", 
                "time_frame": "four weeks"
            }, 
            {
                "measure": "Change from baseline to the end of the Treatment Period in Pain Quality Assessment Scale score", 
                "safety_issue": "No", 
                "time_frame": "four weeks"
            }, 
            {
                "measure": "Rescue medication consumption", 
                "safety_issue": "No", 
                "time_frame": "four weeks"
            }, 
            {
                "measure": "Adverse events (AEs), vital signs, and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "six weeks"
            }, 
            {
                "measure": "Change from baseline to the end of the Treatment Period in Modified Brief Pain Inventory Short Form score, pain interference subscale", 
                "safety_issue": "No", 
                "time_frame": "four weeks"
            }
        ], 
        "source": "NeurAxon Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NeurAxon Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}